Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 18.892 billion yuan, while the Sci-Tech Innovation Board saw a net inflow of 731 million yuan [1] - A total of 217 stocks on the Sci-Tech Innovation Board had net inflows, while 370 stocks had net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 363 stocks rose, with two stocks, Honglida and Zhongke Lanyun, hitting the daily limit, while 215 stocks declined [1] - The top three stocks with the highest net inflow of funds were Haiguang Information (1.264 billion yuan), SMIC (508 million yuan), and Chipone (483 million yuan) [1][2] Continuous Fund Flow - There are 44 stocks with continuous net inflows for more than three trading days, with Cambrian leading at 24 consecutive days of inflow [2] - Conversely, 179 stocks experienced continuous net outflows, with Naike Equipment showing the longest streak at 17 consecutive days [2] Top Fund Inflows - The top stocks by net inflow include: - Haiguang Information: 1263.65 million yuan, with a flow rate of 6.95% and a price increase of 10.70% [2] - SMIC: 507.74 million yuan, with a flow rate of 2.56% and a price increase of 6.25% [2] - Chipone: 483.24 million yuan, with a flow rate of 5.98% and a price increase of 17.34% [2] Notable Outflows - The stock with the highest net outflow was Borui Pharmaceutical, which saw a decline of 13.15% and a net outflow of 367 million yuan [1] - Other notable outflows included Dekeli and Juguang Technology, with net outflows of 235 million yuan and 184 million yuan, respectively [1]

Core Insights - 博瑞医药's stock dropped by 13.15% on September 22, closing at 81.80 yuan [1] - A significant block trade occurred, with a total volume of 26,100 shares and a transaction value of 2.135 million yuan [1] - The first transaction price was 81.80 yuan, with a premium rate of 0.00% [1] Trading Activity - In the last three months, 博瑞医药 has recorded 23 block trades, totaling a transaction value of 220 million yuan [1] - Over the past five trading days, the stock has declined by 10.29%, while the net inflow of main funds amounted to 162 million yuan [1]

| 交易日期 | | 证券代码 > | 成交价(元) 成交盒额[万元) 成交量(*) 买入营业部 | | 美出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | | 025-09-22 | 博瑞医药 | 688166 | 81.8 213.5 2.61 | 患否查雾墙落复露 | 要聚民需要服務 | KO | 9月22日，博瑞医药大宗交易成交2.61万股，成交额213.5万元，占当日总成交额的0.06%，成交价81.8 元，较市场收盘价81.8元持平。 ...

Core Viewpoint - The stock price of Borui Pharmaceutical (688166.SH) has dropped by 13.15%, closing at 81.80 yuan on September 22 [1] Company Summary - Dongwu Securities analyst Zhu Guoguang published a report on September 16, maintaining a "buy" rating for Borui Pharmaceutical [1]

北京商报讯（记者 丁宁）9月22日午后，博瑞医药（688166）股价跳水回落，盘中一度跌逾10%。 交易行情显示，博瑞医药9月22日高开0.47%，盘中一度涨逾8%。截至北京商报发稿，博瑞医药报84.63 元/股，跌幅为10.15%。当日振幅达21.88%。 ...

Group 1 - The A-share market's weight-loss drug concept stocks have weakened significantly, with BoRui Pharmaceutical dropping nearly 10% [1] - Zhongsheng Pharmaceutical experienced a decline of over 8% [1] - ProLogis and ProPace both fell by more than 3% [1]

Group 1 - The core viewpoint of the news is that the weight loss drug sector experienced a significant decline in stock prices after an initial rise, indicating volatility in this market segment [1] - Specifically, Borui Pharmaceutical saw a drop of over 10% after previously rising more than 9% [1] - Other companies in the sector, such as Zhongsheng Pharmaceutical, fell over 7%, while Tianenkang, Kexing Pharmaceutical, Baihua Pharmaceutical, and Jinkaishengke also experienced declines [1]

Market Overview - The Shanghai Composite Index fell by 0.30% on September 19, with 16 industries rising, led by coal and non-ferrous metals, which increased by 1.97% and 1.19% respectively [2] - The automotive and pharmaceutical industries experienced the largest declines, with drops of 1.94% and 1.41% respectively [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 58.733 billion yuan, with 8 industries seeing net inflows [2] - The non-ferrous metals industry had the highest net inflow, amounting to 872 million yuan, while the media industry followed with a net inflow of 692 million yuan and a daily increase of 0.49% [2] - A total of 23 industries experienced net capital outflows, with the computer industry leading at 10.723 billion yuan, followed by the automotive industry with 7.929 billion yuan [2] Pharmaceutical Industry Performance - The pharmaceutical industry saw a decline of 1.41% with a total net capital outflow of 7.085 billion yuan [3] - Out of 474 stocks in the pharmaceutical sector, 65 stocks rose while 405 stocks fell, including one stock hitting the daily limit down [3] - The top three stocks with the highest net inflow in the pharmaceutical sector were: - Borui Pharmaceutical with a net inflow of 130 million yuan - Mindray Medical with 75.259 million yuan - Micron Technology with 73.759 million yuan [3][4] Capital Outflow in Pharmaceutical Sector - The stocks with the largest capital outflows included: - China National Pharmaceutical with a net outflow of 406 million yuan - Furuya Shares with 342 million yuan - Xingqi Eye Medicine with 188 million yuan [5] - Other notable outflows included: - Hengrui Medicine with a net outflow of 172 million yuan - Celgene Medical with 158 million yuan [5][6]

Core Viewpoint - The article discusses the clinical trial approval for BGM0504, a dual agonist of GLP-1 and GIP receptors, which is expected to have potential in treating various metabolic diseases, including obesity and non-alcoholic steatohepatitis (NASH) [4][6]. Group 1: Clinical Trial and Drug Development - On September 16, Borui Biopharmaceuticals (Suzhou) Co., Ltd. announced that its subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. received the clinical trial approval notice from the National Medical Products Administration to conduct trials of BGM0504 tablets in overweight and obese adults [4]. - BGM0504 is designed to activate two downstream signaling pathways, which can help control blood sugar levels, reduce weight, and improve conditions like NASH [6]. - Currently, the injectable form of BGM0504 is in Phase III clinical trials for two indications: type 2 diabetes and weight loss, while the tablet form is being developed for oral administration [7]. Group 2: GLP-1 Drug Class Overview - GLP-1 (glucagon-like peptide-1) is a hormone produced by intestinal L cells and is classified as an incretin. GLP-1 receptor agonists are a new class of hypoglycemic drugs that enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, leading to reduced food intake and lower blood sugar levels [17].

Company Overview - 博瑞医药 (Borui Pharmaceutical) has seen its stock price increase by 213.08% year-to-date, with a recent 3.17% rise over the last five trading days, a 14.32% decline over the last 20 days, and a 71.83% increase over the last 60 days [2] - The company specializes in the research and production of high-end generic drugs and original new drugs, and it is located in Suzhou Industrial Park, Jiangsu Province [2] Financial Performance - For the first half of 2025, 博瑞医药 reported revenue of 537 million yuan, a year-on-year decrease of 18.28%, and a net profit attributable to shareholders of 17.17 million yuan, down 83.85% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 246 million yuan, with 129 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for 博瑞医药 was 9,568, a decrease of 10.11% from the previous period, while the average number of circulating shares per person increased by 11.32% to 44,185 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 3.25 million shares, a decrease of 1.06 million shares from the previous period, and Innovation Drug, which is a new shareholder holding 2.81 million shares [3]